ExpreS2ion Biotech – Presentation of H1 2026 Interim Report

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.

ExpreS2ion is expected to release its H1 2026 interim report on 20 August 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.

Q1 2026 saw operating income rise 132% to KSEK 6,868, largely reflecting higher grant-funded activity, while the operating loss narrowed 6% to KSEK 11,941 and the net loss improved 16% to KSEK 9,590. R&D expenses increased 158% to KSEK 7,092, driven by continued advancement of the ES2B-C001 clinical programme and pass-through subcontracting costs under the VICI-Disease grant, which were offset by corresponding grant income. Cash stood at SEK 21.8m at quarter-end, before the SEK 31.8m gross proceeds from the subsequently completed rights issue.

On the clinical side, the quarter and subsequent weeks brought a string of updates to the Phase I trial of ES2B-C001. Anti-HER2 antibody responses were confirmed in eight of nine, and later nine of nine, evaluable patients across the 50-µg and 150-µg dose cohorts, with titres continuing to rise across dosing visits and remaining elevated at follow-up. The independent DSMB backed continued dose escalation, and the first patient in the 450-µg cohort has since been dosed with no safety signals of concern. Management also introduced an enriched translational analysis programme and a maintenance dosing component while reiterating the end-2026 Phase I readout and mid-2027 Phase II initiation targets.

Beyond ES2B-C001, focus for H1 could also extend to capital situation, the progress on the Nipah programme following the appointment of Northway Biotech as CDMO; and further read-through from Oxford's BIO-002 malaria data for the ExpreS2 platform.

ExpreS2ion Biotech is a vaccine company with a clinically validated protein expression platform (ExpreS2™) and a focused pipeline of vaccine assets. Its lead programme, ES2B-C001, is a HER2-targeted therapeutic breast cancer vaccine in Phase I and the primary near-term value driver. The ExpreS2™ platform supports partnered programmes in malaria, influenza, and Nipah virus, generating value through licensing, milestones, and royalties.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13.49, 08/07-2026.